Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

ABSTRACT: This is a Phase I/Ib study in which the safety of the combination therapy of RMC-4630 and LY3214996 in the treatment of KRAS mutant cancers will be studied.

DISEASE(S): Colorectal Cancer,Non-small Cell Lung Cancer,Kras Mutation-related Tumors,Pancreatic Cancer

PROVIDER: 2379791 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR